luspatercept Archives -

Bristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after

EHA21: Study raises BMS’ hopes for Reblozyl in less severe disease

https://pharmaphorum.com/news/eha21-study-raises-bms-hopes-for-reblozyl-in-less-severe-patients/

Bristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

https://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/

It’s shaping up to be a landmark year for the community of patients with rare blood disorder beta

Celgene gets speedy review for thalassaemia drug luspatercept

https://pharmaphorum.com/news/celgene-gets-speedy-review-for-thalassaemia-drug-luspatercept/

Celgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up

Celgene files potential blockbuster luspatercept

https://pharmaphorum.com/news/celgene-files-potential-blockbuster-luspatercept/

A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have

Celgene scores at ASH18 with double luspatercept data

https://pharmaphorum.com/news/celgene-scores-at-ash18-with-double-luspatercept-data/

luspatercept